Liquidia (LQDA) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

Liquidia (LQDA) overview

Liquidia (LQDA) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 158m and operating profit of USD -51.4m; the year-end share price was 34.49 USD and market capitalisation was USD 3,008m. Liquidia is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Liquidia's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 44.7mFY 2025
Share price34.49 USDFY 2025 year end
RevenueUSD 158mFY 2025
Operating profitUSD -51.4mFY 2025
Net earningsUSD -68.9mFY 2025
Market capitalisationUSD 3,008mFY 2025 year end

About Liquidia

Liquidia develops and commercializes inhaled therapies for pulmonary and vascular diseases using its PRINT drug-particle technology. Its marketed product YUTREPIA is treprostinil inhalation powder approved for pulmonary arterial hypertension. The company is developing L606, an investigational extended-release treprostinil formulation for pulmonary hypertension, and studying YUTREPIA in additional conditions, including systemic sclerosis-associated Raynaud’s phenomenon.

Generate the Liquidia report

Liquidia is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Liquidia and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Liquidia

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.